Nanexa ABFRA:40M +5.06%48 FCF Margin % is -663.16% as of Mar. 2026. GuruFocus rates FRA:40M with a GF Score™ of 48/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 958 Drug Manufacturers companies, Nanexa AB ranks worse than 90.71% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nanexa AB's Free Cash Flow for the
three
months ended in Mar. 2026 was €-1.01 Mil. Nanexa AB's Revenue for the
three
months ended in Mar. 2026 was €0.15 Mil. Therefore, Nanexa AB's FCF Margin % for the quarter that ended in Mar. 2026 was -663.16%.
The historical rank and industry rank for Nanexa AB's FCF Margin % or its related term are showing as below:
FRA:40M'
s FCF Margin % Range Over the Past 10 Years
Min: -10983.81 Med: -1551.7 Max: -68.43
Current: -68.43
During the past 12 years, the highest FCF Margin % of Nanexa AB was -68.43%. The lowest was -10983.81%. And the median was -1551.70%.
FRA:40M's FCF Margin % is ranked worse than 90.71% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs FRA:40M: -68.43
Nanexa AB FCF Margin % Related Terms
Nanexa AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for Nanexa AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanexa AB FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Nanexa AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanexa AB (FRA:40M) has a FCF Margin % of -663.16% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nanexa AB and its competitors. According to the industry distribution chart, Nanexa AB ranks #869 out of 958 companies in the Drug Manufacturers industry, placing it in the top 90.7%.
Is Nanexa AB's FCF Margin % too high?
Nanexa AB's current FCF Margin % is -663.16%. Based on the distribution chart, Nanexa AB ranks #869 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nanexa AB has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nanexa AB ranks #869 out of 958 companies for FCF Margin %. This places Nanexa AB in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nanexa AB and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanexa AB's current FCF Margin % is -663.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.31 — trading 83.2% above its estimated fair value. The current FCF Margin % is -663.16%. Nanexa AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current FCF Margin % is -663.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanexa AB (FRA:40M) Overvalued in 2026?
Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued.
The current stock price of €0.31 is trading 83.2% above its estimated GF Value™ of €0.17.
GuruFocus considers Nanexa AB to be Significantly Overvalued.
Key valuation signals for FRA:40M:
FCF Margin %: -663.16%
GF Value™: €0.17 vs. price of €0.31 (83.2% above fair value)
No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
48GF Score
Get the complete analysis for FRA:40M
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:40M has been successfully added to your 
